Fundraising Fox

Tune Therapeutics

Durham and Seattle, US · Founded 2020 · Delaware corporation · 5 known investors

tunetx.com ↗

Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications. The company works on novel gene network therapies for challenging diseases.

BiotechDeep TechHealthtechLongevityMedical Devicesin /tunetx@tunetx_news

Founders & leadership

AMAkira Matsuno
Akira MatsunoExecutive Officer
DJDerek Jantz
Derek JantzExecutive Officer
CGCharles Gersbach
Charles GersbachDirector
JMJohn McHutchison
John McHutchisonCEO, Chairman of the Board
DMDan McHugh
Dan McHughExecutive Officer, Director
BSBlythe Sather
Blythe SatherExecutive Officer
YZ
Yuan ZhangExecutive Officer
ZHZachary Hale
Zachary HaleExecutive Officer
ABAli Behbahani
Ali BehbahaniDirector

Investors · 5

Duke Capital PartnersDurham
Mission BiocapitalSan Francisco · $500K
Hatteras Venture PartnersreportedResearch Triangle · $500K – $4M
New Enterprise Associates (NEA)reportedMenlo Park · $200K – $40Mvia Ali Behbahani · board
YosemitereportedSan Francisco

Reported raises · per SEC filings

Form D private placements
▶$182.4MraisedJan 2025 · 39 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Dan McHughExecutive Officer, Director
  • Akira MatsunoExecutive Officer
  • Blythe SatherExecutive Officer
  • Derek JantzExecutive Officer
  • Charles GersbachDirector
  • John McHutchisonDirector
  • Yuan ZhangExecutive Officer
  • Zachary HaleExecutive Officer
  • Ali BehbahaniDirector
Offering amount
$208M
Amount sold
$182.4M
First sale
Mar 2023
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news